Water-soluble triptolide prodrug compound and its synthesis method and application

By introducing ethylenediamine-like structure and amide bond connection on triptamine, a water-soluble prodrug was formed, which solved the problems of low water solubility and great toxic side effects, and achieved stable transformation in the body and efficient treatment of idiopathic lungs. The effect of fibrosis.

CN117659038BActive Publication Date: 2024-11-19HUBEI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311655754.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-05
Publication Date
2024-11-19
Estimated Expiration
2043-12-05

AI Technical Summary

Technical Problem

Tributycin has low water solubility, great toxic side effects, and its prodrug conversion is not ideal, resulting in unstable in the body and difficult to be safe and effective in clinical use.

Method used

By introducing ethylenediamine-like structure on the C-14 hydroxyl group of triplothine and connecting through amide bonds, a water-soluble triplothine prodrug compound is formed, which improves its solubility in water and is cyclized through intramolecular cyclization - Eliminate the reaction and release the parent drug, avoiding the reliance on metabolic enzyme transformation in vivo.

Benefits of technology

It significantly improves the water solubility and transformation stability of tributaryl, reduces toxic side effects, prolongs the drug half-life, improves the effect of treating idiopathic pulmonary fibrosis, and provides a new highly efficient and low-toxic drug candidate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117659038B_ABST
    Figure CN117659038B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of medical technology, and in particular to a water-soluble triptolide prodrug compound and a synthesis method and application thereof. The water-soluble triptolide prodrug compound is a compound as shown in Formula I or a pharmaceutically acceptable salt thereof. The solubility of the triptolide prodrug compound provided by the present invention in water can reach more than 2 mg / mL, and it releases the parent drug TP in the body through an intramolecular cyclization-elimination reaction, and has the advantages of stable prodrug conversion rate and extended drug half-life, good water solubility and stable conversion rate ensure the in vivo absorption of the drug and the exertion of drug efficacy, which is conducive to greatly reducing its toxic and side effects, and improving the therapeutic effect of anti-idiopathic pulmonary fibrosis, and providing a new type of high-efficiency and low-toxic candidate drug for the treatment of idiopathic pulmonary fibrosis, with broad market prospects and excellent application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a water-soluble triptolide prodrug compound and a synthesis method and application thereof. Background Art

[0002] Idiopathic pulmonary fibrosis (IPF) is a progressive lower respiratory tract disease of unknown cause, characterized by diffuse alveolitis and alveolar structural disorder, which eventually leads to pulmonary interstitial fibrosis. IPF is fatal and irreversible, characterized by dry cough and progressive dyspnea, which can develop into respiratory failure and even lead to death. The global prevalence of IPF is 0.33-4.51 / 10,000 people, and the incidence is 0.09-1.30 / 10,000 people, with the incidence in men slightly higher than that in women. Most IPF patients will deteriorate to the late stage of the disease within 2-5 years after the onset of symptoms. The median survival of IPF patients is 2-3 years, the 5-year survival rate is less than 30%, and the mortality rate increases with age. Pirfenidone and nintedanib are marketed drugs approved by the US FDA for the treatment of IPF, but these two drugs can only slow down the progression of lung function in IPF patients, have little effect on reversing pulmonary fibrosis, and both have serious adverse reactions. Lung transplantation is currently the only effective method for the clinical treatment of IPF, but the 5-year survival rate after transplantation is less than 42%. Therefore, there is an urgent need to develop new candidate drugs that can reduce or delay pulmonary fibrosis, which is very important for improving the quality of life of IPF patients and reducing mortality.

[0003] Triptolide (TP), also known as triptolide and triptolide alcohol, is an epoxyditerpene lactone compound isolated from Tripterygium wilfordii of the Celastraceae family. Pharmacological studies have shown that TP has strong anti-inflammatory, immunosuppressive, anti-fertility and anti-tumor effects. Importantly, some studies have demonstrated the therapeutic effect of TP in delaying and inhibiting pulmonary fibrosis. Although TP has certain pharmacological activity against pulmonary fibrosis, making it a promising new drug candidate for IPF, its poor water solubility and significant toxic side effects on the digestive system, urogenital system and blood system, especially the liver and kidneys, have hindered its further development and clinical application.

[0004] Due to its poor solubility in water, structural modification of TP, design and synthesis of new water-soluble TP derivatives with good pharmacokinetic properties are one of the main ways to reduce toxicity. At present, it is mainly based on the prodrug principle, by introducing a water-soluble structure into the free hydroxyl group of TP, which becomes active TP after metabolism in the body. This process can change the in vivo pharmacokinetic properties of the parent drug. There are currently two water-soluble TP derivatives that have entered clinical research: 1) PG490-88 is C-14-succinyl triptolide sodium salt, which is hydrolyzed and metabolized by esterase in the body to generate TP, but due to differences in metabolic enzymes between individuals, PG490-88 is slowly and incompletely converted in the body, and the clinical study was terminated in Phase I; 2) Minnelide is C-14-phosphooxymethyl triptolide sodium salt, which is hydrolyzed and converted into TP by phosphatase in the body. As an anti-pancreatic cancer drug, Minnelide has completed Phase II clinical research. The activation of the above two TP derivatives in the body depends on the conversion of metabolic enzymes in the body, which is easily affected by the individual differences in the expression of metabolic enzymes in the body. The degree of conversion to TP is difficult to predict, and there are disadvantages such as too fast degradation and release or incomplete conversion. Therefore, although there have been a lot of studies on triptolide, the problems of low water solubility, large toxicity and side effects, and unsatisfactory prodrug conversion of triptolide are still prominent. How to achieve stable conversion of triptolide prodrug into biologically active triptolide in the body on the basis of improving the water solubility of triptolide prodrug and reducing toxicity and side effects is a key problem that needs to be solved urgently for the safe and effective clinical application of prodrugs. Summary of the invention

[0005] In view of the problems of low water solubility, large toxic and side effects, and unsatisfactory prodrug conversion of triptolide in the prior art, the present invention provides a water-soluble triptolide prodrug compound and a preparation method thereof, and provides the use of the water-soluble triptolide prodrug compound in the preparation of a drug for treating idiopathic pulmonary fibrosis.

[0006] To achieve the above object, the present invention is specifically implemented through the following technical solutions:

[0007] The first aspect of the present invention provides a water-soluble triptolide prodrug compound, which is a compound as shown in Formula I or a pharmaceutically acceptable salt thereof:

[0008]

[0009] In the formula, R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, methyl or ethyl; or, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4The C atoms to which it is bonded combine with each other to form a phenyl group, a cyclohexyl group or a cyclopentyl group; or, R 1 and R 3 are independently selected from hydrogen, methyl or ethyl, R 2 and R 4 The N atom and the C atom bonded thereto are combined with each other to form a pyrrolidyl group.

[0010] Furthermore, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 is selected from hydrogen; or, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 The C atoms to which it is bonded combine with each other to form a phenyl group; or, R 1 is selected from hydrogen, methyl or ethyl, R 3 Selected from hydrogen, R 2 and R 4 The N atom and the C atom bonded thereto are combined with each other to form a pyrrolidyl group.

[0011] Specifically, the water-soluble triptolide prodrug compound is selected from any one of TP-DEA1 to TP-DEA4 or a pharmaceutically acceptable salt thereof;

[0012]

[0013] The second aspect of the present invention provides a method for preparing the water-soluble triptolide prodrug compound as described above, comprising the following steps:

[0014] S1, dissolving triptolide and p-nitrophenyl chloroformate in an organic solvent A, adding a base and a catalyst A under the protection of an inert gas, and performing an esterification reaction to obtain a compound of formula A;

[0015] The structural formula of the compound of formula A is:

[0016]

[0017] S2, dissolving the compound of formula A and the compound of formula B in an organic solvent B, adding a catalyst B, and performing an acylation reaction to obtain a compound of formula C;

[0018] The structural formula of the compound of formula B is:

[0019]

[0020] The structural formula of the compound of formula C is:

[0021]

[0022] S3, dissolving the compound of formula C in an organic solvent C, adding an organic acid, and performing a deamination protecting agent reaction to obtain a compound of formula I;

[0023] In the above formula, R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, methyl or ethyl; or, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 The C atoms to which it is bonded combine with each other to form a phenyl group, a cyclohexyl group or a cyclopentyl group; or, R 1 and R 3 are independently selected from hydrogen, methyl or ethyl, R 2 and R 4 The N atom and C atom bonded to it combine with each other to form a pyrrolidine group; R 5 is selected from benzyloxycarbonyl, tert-butyloxycarbonyl, benzyl or p-methoxybenzyl.

[0024] Furthermore, in step S1, the molar ratio of the triptolide, the p-nitrophenyl chloroformate, the base and the catalyst A is 1:5:5:5, the base is triethylamine, and the catalyst A is 4-dimethylaminopyridine.

[0025] Furthermore, in step S2, the molar ratio of the compound of formula A, the compound of formula B and the catalyst B is 1:1-1.6:0.6-1.6, and the catalyst B is triethylamine or N,N-diisopropylethylamine.

[0026] Further, in step S2, the compound of formula B is selected from at least one of the following formulae:

[0027]

[0028] Furthermore, in step S3, the organic acid is trifluoroacetic acid or an acetic acid solution containing hydrogen bromide.

[0029] The third aspect of the present invention provides the use of the water-soluble triptolide prodrug compound as described above in the preparation of a drug for treating idiopathic pulmonary fibrosis.

[0030] The fourth aspect of the present invention provides a pharmaceutical composition comprising the water-soluble triptolide prodrug compound as described above and pharmaceutically acceptable excipients.

[0031] The advantages and positive effects of the present invention are:

[0032] The present invention introduces an ethylenediamine-like structure on the C-14 hydroxyl group of triptolide (TP), and the two are connected by an amide bond to form a triptolide prodrug compound. The solubility of the compound in water can reach more than 2 mg / mL, which is more than 100 times higher than the solubility of the parent drug TP. Moreover, the prodrug compound releases the parent drug TP through an intramolecular cyclization-elimination reaction in the body, avoiding the difference in drug activity or toxicity caused by the difference in expression of metabolic enzymes in the body, and has the advantages of stable prodrug conversion rate, extended drug half-life, etc. Good water solubility and stable conversion rate ensure the in vivo absorption and efficacy of the drug, which is conducive to reducing adverse reactions, greatly reducing its toxic side effects, and improving the therapeutic effect of anti-idiopathic pulmonary fibrosis. The present invention provides a new type of highly efficient and low-toxic candidate drug for the treatment of idiopathic pulmonary fibrosis, with broad market prospects and excellent application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0034] Figure 1 The stability test results of the triptolide prodrug compound of the present invention are shown in Figure A. Figure A shows the stability of TP-DEA2 in mouse plasma, and Figure B shows the stability of TP-DEA2 in PBS buffer.

[0035] Figure 2 : is the pharmacokinetic curve of the triptolide prodrug compound of the embodiment of the present invention;

[0036] Figure 3 These are the serological indicators of mice after continuous intraperitoneal injection of triptolide prodrug compounds for two weeks according to the embodiments of the present invention, wherein Figure A is a serological indicator of liver function, and Figure B is a serological indicator of kidney function;

[0037] Figure 4 The staining images of the kidney (upper) and liver (lower) tissue sections of mice after continuous intraperitoneal injection of triptolide prodrug compound for two weeks according to the embodiment of the present invention;

[0038] Figure 5 This is a staining image of mouse lung tissue sections after continuous intraperitoneal injection of triptolide prodrug compounds for two weeks according to an example of the present invention. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0040] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.

[0041] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values ​​used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.

[0042] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art. The meanings of the terms "comprise", "include", "contain", "have" and the like are non-restrictive, i.e., other steps and other ingredients that do not affect the result can be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" will be regarded as including the following situations: (i) A, (ii) B, and (iii) A and B.

[0043] The term "prodrug" or "prodrug" refers to a compound that has no biological activity or very low activity in vitro, but is converted into an active parent drug through enzymatic or non-enzymatic metabolism in vivo to exert its pharmacological effect. In the present invention, triptolide prodrug means that the prodrug can be converted into the parent drug - triptolide (TP) in vivo.

[0044] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the present invention is described in detail below.

[0045] The present invention provides a water-soluble triptolide prodrug compound, which is a compound as shown in Formula I or a pharmaceutically acceptable salt thereof:

[0046]

[0047] In the formula, R 1 , R 2 , R 3 and R 4 independently selected from hydrogen (—H), methyl (—CH 3 ) or ethyl (-CH 2 H 3 ); or, R 1 and R 2 independently selected from hydrogen (—H), methyl (—CH 3 ) or ethyl (-CH 2 H 3 ), R 3 and R 4 The C atoms to which it is bonded combine with each other to form a phenyl group, a cyclohexyl group or a cyclopentyl group; or, R 1 and R 3 independently selected from hydrogen (—H), methyl (—CH 3 ) or ethyl (-CH 2 H 3 ), R 2 and R 4 The N atom and the C atom bonded thereto are combined with each other to form a pyrrolidyl group.

[0048] The structural formulas of the phenyl, cyclohexyl, cyclopentyl and pyrrolidinyl groups are shown below, respectively, and the wavy lines represent the connecting bonds:

[0049]

[0050] The present invention introduces an ethylenediamine-like structure into the C-14 hydroxyl group of triptolide (TP), and the two are connected by an amide bond to form a triptolide derivative. Multiple hydrophilic groups such as amino groups are introduced into the molecular structure of the derivative, which can greatly improve the solubility of the compound. After testing, the solubility of multiple compounds with the general structure shown in Formula I in water can reach more than 2 mg / mL, which is more than 100 times higher than the solubility of TP in water of 17 μg / mL. In addition, the amino group is used as a basic group, and the introduction of the amino group can facilitate the salt formation of the compound, thereby further improving the water solubility of the compound. On the other hand, the compound with the general structure shown in Formula I can be used as a triptolide prodrug, and the nucleophilic group amino group near the end of the molecule attacks the carbonyl carbon atom, and an intramolecular cyclization-elimination reaction occurs, and then TP is released from the prodrug. The process of its conversion into TP does not involve the mechanism of ester bond hydrolysis, thereby avoiding the difference in drug activity or toxicity caused by the difference in the expression of metabolic enzymes in the body. The pharmacological activity experiment shows that after the compound of the present invention enters the body, it can be converted into TP at a predictable conversion rate, and has the advantages of stable prodrug conversion rate and extended half-life of the parent drug. Good water solubility and stable conversion rate are conducive to the in vivo absorption and efficacy of the drug, thereby reducing adverse reactions, greatly reducing its toxic side effects, and improving drug safety. After continuous administration for 2 weeks on the bleomycin-induced mouse idiopathic pulmonary fibrosis (IPF) model, the prodrug compound of the present invention has significantly reduced toxicity to tissues such as the liver and kidney, and can significantly reduce lung tissue inflammation and inhibit bleomycin-induced lung tissue fibrosis. The improvement of mouse lung tissue pathological fibrosis is better than that of the positive drug nibendazim, and has a good anti-idiopathic pulmonary fibrosis effect, providing a new type of high-efficiency, low-toxic candidate drug for the treatment of idiopathic pulmonary fibrosis, with broad market prospects and excellent application value.

[0051] The mechanism by which the prodrug compounds of the present invention are converted into TP is as follows:

[0052]

[0053] Preferably, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 is selected from hydrogen; or, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 The C atoms to which it is bonded combine with each other to form a phenyl group; or, R 1 is selected from hydrogen, methyl or ethyl, R 3 Selected from hydrogen, R 2 and R 4The N atom and the C atom bonded thereto are combined with each other to form a pyrrolidyl group.

[0054] "Independently" indicates that there is no conflict between the selection of the groups, which can be the same or different. 1 , R 2 For example, both can be hydrogen, or one of them can be hydrogen and the other can be methyl or ethyl.

[0055] Specifically, the triptolide prodrug compound is selected from any one of TP-DEA1 to TP-DEA4 or a pharmaceutically acceptable salt thereof;

[0056]

[0057] Another embodiment of the present invention provides a method for preparing the water-soluble triptolide prodrug compound as described above, comprising the following steps:

[0058] S1, dissolving triptolide and p-nitrophenyl chloroformate in an organic solvent A, adding a base and a catalyst A under the protection of an inert gas, and performing an esterification reaction to obtain a compound of formula A;

[0059] The structural formula of p-nitrophenyl chloroformate (NPC) is:

[0060]

[0061] The structural formula of the compound of formula A (TP-NPC) is:

[0062]

[0063] S2, dissolving the compound of formula A and the compound of formula B in an organic solvent B, adding a catalyst B, and performing an acylation reaction to obtain a compound of formula C;

[0064] The structural formula of the compound of formula B is:

[0065]

[0066] The structural formula of the compound of formula C is:

[0067]

[0068] S3, dissolving the compound of formula C in an organic solvent C, adding an organic acid, and performing a deamination protecting agent reaction to obtain a compound of formula I;

[0069] In the above formula, R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, methyl or ethyl; or, R 1 and R2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 The C atoms to which it is bonded combine with each other to form a phenyl group, a cyclohexyl group or a cyclopentyl group; or, R 1 and R 3 are independently selected from hydrogen, methyl or ethyl, R 2 and R 4 The N atom and C atom bonded to it combine with each other to form a pyrrolidine group; R 5 One selected from amino protecting groups such as benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), benzyl (Bn) and p-methoxybenzyl (PMB).

[0070] The preparation method of the water-soluble triptolide prodrug compound has the same advantages as the above-mentioned water-soluble triptolide prodrug compound over the prior art, which will not be described in detail here.

[0071] Optionally, in the esterification reaction of step S1, the molar ratio of the triptolide, the p-nitrophenyl chloroformate, the base and the catalyst A is 1:5:5:5, the base is triethylamine (TEA), the catalyst A is 4-dimethylaminopyridine (DMAP), and the organic solvent A is tetrahydrofuran (THF);

[0072] Optionally, in the acylation reaction of step S2, the molar ratio of the compound of formula A, the compound of formula B and the catalyst B is 1:1-1.6:0.6-1.6, the catalyst B is triethylamine or N,N-diisopropylethylamine (DIPEA), and the organic solvent B is N,N-dimethylformamide (DMF).

[0073] Optionally, in the deamination protecting agent reaction of step S3, the organic acid is trifluoroacetic acid (TFA) or an acetic acid solution containing hydrogen bromide, and the organic solvent C is dichloromethane (DCM).

[0074] Optionally, the compound of formula B is selected from at least one of the following formulae:

[0075]

[0076] Another embodiment of the present invention provides the use of the water-soluble triptolide prodrug compound as described above in the preparation of an anti-idiopathic pulmonary fibrosis drug.

[0077] The use of the water-soluble triptolide prodrug compound in the preparation of an anti-idiopathic pulmonary fibrosis drug has the same advantages as the water-soluble triptolide prodrug compound described above over the prior art, which will not be described in detail here.

[0078] Yet another embodiment of the present invention provides a pharmaceutical composition, comprising the water-soluble triptolide prodrug compound as described above and pharmaceutically acceptable excipients.

[0079] The present invention uses the compound shown in formula I or a pharmaceutically acceptable salt thereof as the active ingredient in the pharmaceutical composition, which can be stably converted into triptolide in the body, has the effects of improving lung tissue damage, reducing lung tissue inflammation and pulmonary fibrosis, and has better effects than the classic anti-idiopathic pulmonary fibrosis (IPF) drug nibendazim, and is expected to be a new candidate drug for the treatment of IPF.

[0080] "Pharmaceutical composition" refers to a preparation of a compound represented by Formula I of the present invention or a pharmaceutically acceptable salt thereof and a medium generally accepted in the art for delivering biologically active compounds to mammals (e.g., humans), the medium including pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0081] "Pharmaceutically acceptable salts" are salts that retain the biological effectiveness and properties of the compound comprising the structure of Formula I (i.e., the parent compound) without other side effects. They include, but are not limited to: (1) acid salts, obtained by reacting the free base of the parent compound with an inorganic acid or an organic acid, such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, sulfurous acid and perchloric acid, or an organic acid such as formic acid, acetic acid, propionic acid, acrylic acid, caprylic acid, oxalic acid, malic acid, fumaric acid, maleic acid, hydroxybenzoic acid, γ-hydroxybutyric acid, phthalic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, palmitic acid, stearic acid, oleic acid, cinnamic acid, lauric acid, lactic acid, succinic acid or malonic acid; (2) ) Salts formed by the replacement of acidic protons in the parent compound by metal ions or coordination with inorganic bases or organic bases, such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum ions, etc., and organic bases such as ammonia, trimethylamine, diethylamine, ethylenediamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, choline, betaine, glucosamine, methylglucosamine, etc. These salts can be prepared by methods well known in the art.

[0082] "Pharmaceutically acceptable excipients" refer to components that do not interfere with the efficacy of the biological activity of the active ingredient (compound of formula I or its pharmaceutically acceptable salt) and are not significantly toxic to the body at the therapeutically effective concentration of the administered compound, including any one or a combination of at least two of solvents, dispersants, diluents, fillers, wetting agents, adhesives, disintegrants, lubricants, preservatives, suspending agents, emulsifiers, excipients, flavoring agents, etc. and carriers. It is well known in the art to use the aforementioned components for pharmaceutically active substances. For example, solvents include but are not limited to water, buffered saline solutions and organic solvents; carriers include but are not limited to polyethylene glycol, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, gypsum powder, sucrose, cyclodextrin, straight-chain starch, magnesium stearate, talc, agar, pectin, gum arabic, stearic acid or cellulose lower alkyl ethers, silicic acid, fatty acids, fatty amides, fatty acid monoglycerides or diglycerides, tetraglycerol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. The carrier may also include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

[0083] "Treatment" generally refers to obtaining a desired pharmacological and / or physiological effect. The effect may be preventive, in terms of completely or partially preventing a disease or its symptoms; and / or therapeutic, in terms of partially or completely stabilizing or curing a disease and / or side effects resulting from a disease. As used herein, "treating" encompasses any treatment of a patient's disease, including: (a) preventing a disease or symptom from occurring in a patient who has not yet been diagnosed with the disease; (b) inhibiting the symptoms of a disease, i.e., preventing its development; or (c) alleviating the symptoms of a disease, i.e., causing the disease or symptom to regress.

[0084] The compounds provided by the present invention can be adapted to any form of administration, including but not limited to oral, nasal, transdermal, intravenous and parenteral administration. Those skilled in the art can select a suitable preparation form according to the administration mode, for example, when used for oral administration, conventional solid preparations and liquid preparations can be prepared, including but not limited to pills, tablets, chewables, capsules, granules, suspensions, drops or syrups, etc., and for example, when used for parenteral administration, suspensions, injections or sprays, etc. can be prepared but not limited to.

[0085] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples without specifying specific conditions are generally carried out according to the conditions recommended by the manufacturer.

[0086] The synthetic routes of the target compounds (corresponding to the three cases of Formula I) in the following examples are shown in Equations 1 to 3:

[0087]

[0088] Equation 1 (esterification reaction)

[0089]

[0090] Formula 2 (acylation reaction)

[0091]

[0092] Formula 3 (deamination protecting agent)

[0093] In the above formula, R 1 , R 2 , R 3 and R 4 independently selected from one of hydrogen, methyl or ethyl; X is selected from phenyl, cyclohexyl or cyclopentyl, R 5 Selected from amino protecting groups such as Boc, Cbz, Bn or PMB.

[0094] Example 1 Synthesis of TP-DEA1

[0095] The structural formula of TP-DEA1 (R 1 =H, R 2 =H, R 3 =H, R 4 =H) is as follows:

[0096]

[0097] Step 1: Synthesis of intermediate TP-NPC

[0098] As shown in equation 1, 2 mL of anhydrous tetrahydrofuran (THF), 0.056 mmol of triptolide (TP) and 0.28 mmol of p-nitrophenyl chloroformate (NPC) were added to a 10 mL double-necked round-bottom flask, nitrogen was introduced and the flask was placed in an ice-water bath, and the aforementioned substances were dissolved by stirring. Then, 0.28 mmol of anhydrous triethylamine (TEA) and 0.28 mmol of 4-dimethylaminopyridine (DMAP) were dissolved in 2 mL of anhydrous THF, and slowly added dropwise to the flask, stirred for 24 h, and the reaction was detected by thin layer chromatography (TLC). The solvent THF was removed by vacuum concentration, 5 mL of dichloromethane (DCM) was added, and saturated sodium bicarbonate (Na 2 CO 3 ), washed with saturated salt water (NaCl), anhydrous sodium sulfate (Na 2 SO 4 ) and concentrated to obtain an oily crude product, namely compound TP-NPC. This crude product can be directly used for the next step without purification.

[0099] Step 2: Synthesis of intermediate compound C

[0100] As shown in equation 2, 2 mL of anhydrous N,N-dimethylformamide (DMF) was added to a 15 mL double-necked round-bottom flask, TP-NPC (0.28 mmol) and anhydrous triethylamine (0.28 mmol) in the above step were added, nitrogen was passed through and placed in an ice-water bath and stirred, 2-aminoethylcarbamic acid tert-butyl ester (CAS: 57260-73-8) was dissolved in anhydrous DMF in an equal molar ratio, and it was slowly added dropwise to the flask through a syringe and stirred overnight. The reaction was quenched with an appropriate amount of saturated ammonium chloride aqueous solution, extracted with ethyl acetate (EA), the organic phases were combined, and saturated Na 2 CO 3 Aqueous solution washing, anhydrous Na 2 SO 4 After drying and concentration, a colorless oily crude product was obtained, which was purified by semi-preparative high performance liquid chromatography and dried to obtain a white solid. The structure of compound C was confirmed by identification, and the yield was 36%. For the convenience of description, the compounds C in different embodiments are respectively referred to as C1, C2, C3 and C4. The H NMR spectrum data of compound C1 in this embodiment are: 1 H NMR(400MHz,Chloroform-d)δ5.31(d,1H),4.93(s,1H),4.84(s,1H),4.67(qd,J=3.2,2.0Hz,2H) ,3.83(d,J=3.2Hz,1H),3.49(dd,2H),3.42–3.22(m,4H),2.69(d,J=13.3Hz,1H),2.32(d,J=18.0H z,1H),2.17(dt,J=14.7,5.8Hz,2H),1.99–1.85(m,2H),1.57(dd,J=12.6,5.2Hz,1H),1.44(s,9H ),1.22(td,J=12.1,5.8Hz,1H),1.06(s,3H),0.99(d,J=6.9Hz,3H),0.86(d,J=6.9Hz,3H).[M+Na] + :569.2475.

[0101] The structural formula of tert-butyl 2-aminoethylcarbamate is as follows:

[0102]

[0103] The structural formula of compound C1 is as follows:

[0104]

[0105] Step 3: Synthesis of compound TP-DEA1

[0106] As shown in equation 3, 1 mL of dichloromethane (DCM) was added to a 10 mL single-necked round-bottom flask, 0.018 mmol of compound C1 was added and stirred, 0.5 mL of trifluoroacetic acid (TFA) was added dropwise to the flask, and stirred for 3 h. The crude product was concentrated under reduced pressure to obtain a colorless oily product. The product was separated and purified by semi-preparative high performance liquid chromatography, and the collected samples were combined and dried to obtain a white solid. The structure was confirmed to be TP-DEA1 after identification, and the yield was 45%. The H NMR spectrum data of TP-DEA1 is: 1 HNMR(400MHz, Methanol-d4)δ4.92–4.85(m,3H),4.20–4.12(m,1H),3.94–3.87(m,1H),3.80(t,J= 5.1Hz,1H),3.66(d,J=5.6Hz,1H),3.53–3.33(m,3H),3.20–3.04(m,2H),2.32–2.17(m,2H),2.08( d,J=6.6Hz,1H),1.99–1.81(m,2H),1.45(dd,J=12.7,5.3Hz,1H),1.32(td,J=12.2,6.0Hz,1H),1. 13–1.01(m,1H),0.95(d,J=3.2Hz,3H),0.90(d,J=7.0Hz,3H),0.81(dd,J=10.6,6.4Hz,3H).[M+H] + :447.2131.

[0107] Example 2 Synthesis of TP-DEA2

[0108] The structural formula of TP-DEA2 (R 1 =CH 3 , R 2 =CH 3 , R 3 =H, R 4 =H) is as follows:

[0109]

[0110] Step 1 and step 2 are basically the same as Example 1, except that in step 2, compound B is replaced by [2-(methylamino)ethyl]methylcarbamic acid tert-butyl ester (CAS: 112257-19-9), the amount of triethylamine and [2-(methylamino)ethyl]carbamic acid tert-butyl ester is 0.44 mmol, and the yield of compound C2 is 30%. The H NMR spectrum data of compound C2 is: 1H NMR(400MHz,Chloroform-d)δ5.31(s,1H),4.93(d,J=19.8Hz,1H),4.67(s,2H),3.82(d,J =3.2Hz,1H),3.62–3.25(m,7H),3.04(s,1H),2.98(d,J=4.3Hz,4H),2.89(s,1H),2.69(s,1 H),2.32(d,J=17.9Hz,1H),2.23–2.10(m,2H),1.99–1.85(m,2H),1.46(s,9H),1.29(d,J=6 .4Hz,1H),1.05(d,J=1.8Hz,3H),0.99(dd,J=7.1,2.4Hz,3H),0.87(d,J=6.9Hz,3H).[M+H] + :574.2969.

[0111] The structural formula of tert-butyl [2-(methylamino)ethyl]methylcarbamate is as follows:

[0112]

[0113] Tert-butyl [2-(methylamino)ethyl]methylcarbamate is commercially available or can be synthesized by conventional methods. This embodiment exemplarily provides a synthetic route, comprising the following steps:

[0114]

[0115] Add 50 mL of dichloromethane (DCM) and 42 mmol of N,N'-dimethylethylenediamine to a round-bottom flask, place it in an ice-water bath, and slowly drop 15 mmol of di-tert-butyl pyrocarbonate (Boc) 2 O in DCM solution until the reaction is complete. Add saturated NaHCO 3 The mixture was washed with aqueous solution, acidified by adding 10% acetic acid, then alkalized by adding NaOH, extracted with DCM, and anhydrous Na 2 SO 4 Drying and concentration gave an oily product, the structure of which was confirmed by identification. The H NMR data of tert-butyl [2-(methylamino)ethyl]carbamate was as follows: 1 H NMR(400MHz,Chloroform-d)δ3.34(q,2H),2.90(s,3H),2.72(t,2H),2.46(s,3H),1.45(s,9H).[M+H] + :189.3.

[0116] The structural formula of compound C2 is as follows:

[0117]

[0118] Step 3: Synthesis of compound TP-DEA2

[0119] As shown in equation 3, 1 mL of DCM was added to a 10 mL single-necked round-bottom flask, 0.018 mmol of compound C2 was added and stirred, 0.5 mL of TFA was added dropwise to the flask, and stirred for 2 h. The crude product was concentrated under reduced pressure to obtain a colorless oily product. The product was separated and purified by semi-preparative high performance liquid chromatography, and the collected samples were combined and dried to obtain a white solid. The structure was confirmed to be TP-DEA2 after identification, with a yield of 25%. The H NMR spectrum data of TP-DEA2 are: 1 H NMR(400MHz, Methanol-d4)δ4.93(s,1H),4.84–4.76(m,2H),4.08–3.95(m,1H),3.88(dd,J=10.1,5.0Hz,1H), 3.72(s,1H),3.64(d,J=3.1Hz,1H),3.58–3.47(m,2H),3.08(s,1H),2.99(s,2H),2.89(s,1H),2.78(d,J=14.9 Hz,3H),2.74(s,1H),2.28(td,J=17.2,16.1,8.8Hz,2H),2.13–2.02(m,1H),1.97–1.86(m,2H),1.49(dd,J=12 .7,5.3Hz,1H),1.37–1.31(m,1H),1.07–1.02(m,3H),0.98(dd,J=6.9,4.4Hz,3H),0.86(d,J=7.0Hz,3H).[M+H] + 475.2444.

[0120] It should be noted that, based on the same principles and steps as in the above-mentioned Example 1-2, compound B is selected as [2-(methylamino)ethyl]carbamic acid tert-butyl ester (CAS: 122734-32-1) to synthesize R 1 =CH 3 , R 2 =H, R 3 =H, R 4 =H TP prodrug compound, [2-(methylamino)ethyl]carbamic acid tert-butyl ester structural formula is as follows:

[0121]

[0122] Based on the same principles and steps as in Example 1-2 above, compound B was selected as [2-(ethylamino)ethyl]carbamic acid tert-butyl ester (CAS: 113283-93-5) to synthesize R1 =CH 2 CH 3 , R 2 =H, R 3 =H, R 4 =H TP prodrug compound, [2-(ethylamino)ethyl]carbamic acid tert-butyl ester structural formula is as follows:

[0123]

[0124] Based on the same principles and steps as in Example 1-2 above, compound B is selected as [(2-amino)ethyl]ethylcarbamic acid tert-butyl ester (CAS: 105628-63-5) to synthesize R 1 =H, R 2 =CH 2 CH 3 , R 3 =H, R 4 =H TP prodrug compound, [(2-amino)ethyl]ethylcarbamic acid tert-butyl ester structural formula is as follows:

[0125]

[0126] Example 3 Synthesis of TP-DEA3

[0127] The structural formula of TP-DEA3 (R 1 =CH 3 , R 3 =H, R 2 and R 4 Cyclization to form the pyrrolidinyl group) is as follows:

[0128]

[0129] The synthetic route of compound B is as follows:

[0130]

[0131] Synthesis of compound a: Add L-prolinamide (2.3 g, 20 mmol) and sodium bicarbonate (4.2 g, 50 mmol) to a 500 mL round-bottom flask, stir and dissolve in an ice-water bath, dissolve benzyl chloroformate (5.1 g, 30 mmol) in anhydrous THF, slowly drop into the flask, concentrate after the reaction, and obtain a colorless oily crude product. A white solid product is obtained by column (petroleum ether: ethyl acetate (PE: EA) = 3:1), and the structure of compound a is confirmed by identification, with a yield of 70%. The H NMR spectrum data of compound a is: 1H NMR(400MHz,Chloroform-d)δ7.34(q,J=8.0,6.3Hz,5H),6.82–6.60(m,1H),5.50(s,1H),5.21–5 .11(m,2H),4.36(s,1H),3.65–3.29(m,2H),2.27(d,J=71.0Hz,2H),1.92(d,J=12.8Hz,3H).[M+H] + :249.1.

[0132] Synthesis of compound b: Add compound a (3.5 g, 14 mmol), pyridine (2.2 g, 28 mmol), and anhydrous THF (25 mL) into a 500 mL double-necked round-bottom flask, slowly drop trifluoroacetic anhydride (TFAA) (3.5 g, 17 mmol) into the flask, stir overnight at room temperature, and concentrate to dryness. Purify by silica gel column chromatography (PE: EA = 4: 1) to obtain compound b with a yield of 87%. The H NMR spectrum data of compound b is: 1 H NMR(400MHz,Chloroform-d)δ7.48–7.31(m,5H),5.26–5.13(m,2H),4.59(ddd,J=27.4,7.5,2.7Hz,1H),3. 59(tdt,J=10.4,7.1,3.3Hz,1H),3.44(dt,J=16.1,8.1Hz,1H),2.33–2.00(m,3H),1.89–1.67(m,1H).[M+H] + :231.2.

[0133] Synthesis of compound c: Add compound b (2.8 g, 12 mmol), nickel chloride hexahydrate (282 mg, 1.2 mmol), and anhydrous THF (30 mL) to a 100 mL double-necked round-bottom flask, place under an ice-water bath and start stirring, slowly add sodium borohydride (3 g, 80 mmol) in batches, stir at 0°C, and concentrate under reduced pressure after the reaction is complete to obtain a crude product. Purify by column chromatography (methanol: dichloromethane (MeOH: DCM) = 9:1) to obtain compound c with a yield of 82%. The H NMR spectrum data of compound c is: 1H NMR(400MHz,Chloroform-d)δ7.43–7.30(m,5H),5.24–5.05(m,2H),4.64(s,1H),4.28(s,1H),4.17–4.03(m,1H),3.53(dt,J=10.8,7 .3Hz,1H),3.40(dt,J=10.9,6.4Hz,1H),2.99–2.71(m,2H),2.16–2.02(m,1H),1.93–1.81(m,2H),1.61(dq,J=12.1,6.0Hz,1H).[M+H] + :235.3.

[0134] Synthesis of compound d: Compound c (2.3 g, 9.8 mmol), triethylamine (TEA) (1 g, 10 mmol), and methanol (MeOH) were added to a 100 mL double-necked flask to dissolve, and di-tert-butyl dicarbonate (Boc) was added. 2 O (4.4 g, 20 mmol), placed in an ice-water bath and stirred, TLC monitored the reaction to be complete. Concentrated under reduced pressure to obtain a crude product. Purified by column (PE: EA = 4: 1) to obtain compound d, with a yield of 92%. The H NMR spectrum data of compound d is: 1 H NMR(400MHz,Chloroform-d)δ7.41–7.28(m,5H),5.50(s,1H),5.14(d,J=2.0Hz,2H),4.00–3.87(m, 1H),3.56–3.38(m,2H),3.37–3.15(m,2H),2.06–1.79(m,4H),1.78–1.70(m,1H),1.43(s,9H).[M+H] + :335.1.

[0135] Synthesis of compound e: Compound d (3.0 g, 9.0 mmol), potassium iodide (MeI) (3.3 g, 23 mmol), tetrahydrofuran (THF) (40 ml) were added to a 250 mL double-necked round-bottom flask, and sodium hydride (NaH) (7.7 g, 54 mmol) was slowly added to the flask in sequence. The reaction was monitored by TLC. A yellow crude product was obtained by vacuum rotary evaporation. Compound e was obtained by column purification (PE: EA = 5: 1) with a yield of 32%. The H NMR spectrum data of compound e is: 1H NMR(400MHz,Chloroform-d)δ7.44–7.28(m,5H),5.25–4.99(m,2H),4.05(h,J=13.4,12.6Hz,1H),3.60–3.29(m,3H ),3.28–3.00(m,1H),2.91(d,J=3.9Hz,2H),2.72(d,J=15.3Hz,1H),2.05–1.72(m,4H),1.45(d,J=7.7Hz,9H).[M+H] + :349.1.

[0136] Synthesis of compound B: Compound e (1.0 g, 2.9 mmol), anhydrous DCM, and trifluoroacetic acid (TFA) were added to a 25 mL single-necked round-bottom flask, stirred for 2 h, and concentrated under reduced pressure to obtain a pink oily product. The structure of compound B was confirmed by identification, and the yield was 95%. The H NMR spectrum data of compound B is: 1 H NMR(400MHz, Deuterium Oxide)δ7.41–7.26(m,5H),5.06(d,J=3.1Hz,2H),4.11(dddd,J=24.7,10.4,7.3,4.6Hz,1H),3.47–3.25(m,2H),3.04(d,J=6.4Hz,1 [M+H] + :249.1.

[0137] The synthesis steps of TP-DEA3 are the same as those in Example 1.

[0138] Step 2: Synthesis of intermediate compound C3

[0139] As shown in equation 2, TP-NPC, intermediate compound B (62 mg, 0.17 mmol), N,N-diisopropylethylamine (DIPEA) (44 mg, 0.34 mmol), and anhydrous DMF (100 μL) were added to a 10 mL double-necked round-bottom flask, nitrogen was introduced and placed in an ice-water bath and stirred, 2 mL of anhydrous DCM was added to dissolve, and the mixture was gradually restored to room temperature and stirred overnight. After the reaction was completed, the crude product was concentrated and purified by column (PE: EA = 1: 1) to obtain compound C3 with a yield of 21%. The H NMR spectrum data of compound C3 are: 1H NMR(400MHz,Chloroform-d)δ7.40–7.28(m,5H),5.19–5.08(m,2H),4.99(d,J=12.5Hz,1H),4.67(s,2H),4.15–3.96(m,1H),3.81(dd,J= 5.5,3.1Hz,1H),3.70(ddd,J=19.8,13.6,9.6Hz,1H),3.53–3.42(m,3H),3.34(ddd,J=33.3,11.7,5.0Hz,1H),3.15–3.01(m,2H),2.87(d, J=12.9Hz,1H),2.79(s,1H),2.69(d,J=12.6Hz,1H),2.38–2.27(m,1H),2.23–2.08(m,3H),1.88(dq,J=14.6,6.8Hz,4H),1.71(s,1H),1. 55(dd,J=12.0,5.7Hz,1H),1.21(dt,J=12.0,6.3Hz,1H),1.08–1.00(m,3H),0.99–0.93(m,3H),0.86(ddd,J=21.3,6.5,3.4Hz,3H).[M+H] + :635.2969.

[0140] The structural formula of compound C3 is as follows:

[0141]

[0142] Step 3: Synthesis of compound TP-DEA3

[0143] As shown in equation 3, compound C3 (5.0 mg, 0.008 mmol) was added to a 10 mL single-necked round-bottom flask, acetic acid (0.5 mL) was added to dissolve, 30% hydrogen bromide acetic acid solution (HBr / AcOH) (8.6 mg, 0.032 mmol) was slowly added dropwise, and stirred at room temperature overnight to obtain a red turbid liquid. The crude product was concentrated under reduced pressure. After column (dichloromethane: methanol (DCM: MeOH) = 5: 1), a yellow oily product compound TP-DEA3 was obtained, and the yield was 67.9%. The H NMR spectrum data of compound TP-DEA3 are: 1H NMR (400MHz, Methanol-d4) δ4.83(d,J=3.1Hz,4H),4.40(d,J=4.3Hz,1H),3.98(s,1H),3.77(d,J=4.3H z,1H),3.58(d,J=5.4Hz,1H),2.90(s,4H),2.87(s,1H),2.32(dt,J=15.0,5.9Hz,2H),2.24(d,J=5.4Hz ,1H),2.14(dt,J=10.3,6.7Hz,3H),2.01(dd,J=15.0,13.1Hz,1H),1.61–1.52(m,2H),1.38(ddd,J=15. 7,10.8,4.8Hz,2H),1.32–1.24(m,2H),1.16(s,3H),1.09(d,J=6.7Hz,3H),0.95(d,J=6.8Hz,3H).[M+H] + :501.2601.

[0144] It should be noted that, based on the same principles and steps as in Example 3 above, compound c is used as a substrate to react to obtain R 1 =H, R 3 =H, R 2 and R 4 Cyclization forms the pyrrolidinyl TP derivative.

[0145] Example 4 Synthesis of TP-DEA4

[0146] The structural formula of TP-DEA4 (R 1 =H, R 2 =H, R 3 and R 4 Cyclization to form phenyl) is as follows:

[0147]

[0148] Step 1 and step 2 are the same as in Example 1, except that in step 2, compound B is replaced by tert-butyl (2-aminophenyl)carbamate (CAS: 146651-75-4), and the amount of triethylamine and tert-butyl [2-(methylamino)ethyl]carbamate is 0.44 mmol. The H NMR spectrum data of the intermediate compound C4 are: 1HNMR(400MHz,Chloroform-d)δ7.31(dd,J=7.8,1.4Hz,1H),7.04(td,J=7.7,1.5Hz,1H),6.91(td,J=7.7,1.5Hz,1H),6.78 (dd,J=7.7,1.4Hz,1H),4.92–4.85(m,3H),4.20–4.12(m,1H),3.94–3.87(m,1H),3.80(t,J=5.1Hz,1H),3.66(d,J=5.6Hz,1 H),3.53–3.33(m,1H),2.32–2.17(m,2H),2.08(d,J=6.6Hz,1H),1.99–1.81(m,2H),1.45(dd,J=12.7,5.3Hz,10H),1.32(t d,J=12.2,6.0Hz,1H),1.13–1.01(m,1H),0.95(d,J=3.2Hz,3H),0.90(d,J=7.0Hz,3H),0.81(dd,J=10.6,6.4Hz,3H).[M+H] + :595.2569.

[0149] The structural formula of tert-butyl (2-aminophenyl)carbamate is as follows:

[0150]

[0151] The structural formula of compound C4 is as follows:

[0152]

[0153] Step 3: Synthesis of compound TP-DEA4

[0154] As shown in equation 3, 1 mL of DCM was added to a 10 mL single-necked round-bottom flask, 0.018 mmol of compound C4 was added and stirred, 0.5 mL of TFA was added dropwise to the flask and stirred for 2 h. The crude product was concentrated under reduced pressure to obtain a colorless oily product. The product was separated and purified by semi-preparative high performance liquid chromatography, and the collected samples were combined and dried to obtain a white solid. The structure was confirmed to be TP-DEA4 after identification, with a yield of 75.2%. The H NMR spectrum data of compound TP-DEA4 are: 1H NMR(400MHz,Chloroform-d)δ7.31(dd,J=7.8,1.4Hz,1H),7.04(td,J=7.7,1.5Hz,1H),6.91(td,J=7.7,1.5Hz,1H),6.78( dd,J=7.7,1.4Hz,1H),4.92–4.85(m,3H),4.20–4.12(m,1H),3.94–3.87(m,1H),3.80(t,J=5.1Hz,1H),3.66(d,J=5.6Hz,1 H),3.53–3.33(m,1H),2.32–2.17(m,2H),2.08(d,J=6.6Hz,1H),1.99–1.81(m,2H),1.45(dd,J=12.7,5.3Hz,1H),1.32(td ,J=12.2,6.0Hz,1H),1.13–1.01(m,1H),0.95(d,J=3.2Hz,3H),0.90(d,J=7.0Hz,3H),0.81(dd,J=10.6,6.4Hz,3H).[M+H] + 495.2044.

[0155] It should be noted that, based on the same principles and steps as in Example 4 above, compound B is selected as (2-aminocyclohexyl)carbamic acid tert-butyl ester (CAS: 317595-54-3) to synthesize R 1 =H, R 2 =H, R 3 and R 4 The TP prodrug compound that cyclizes to form a cyclohexyl group, (2-aminocyclohexyl)carbamic acid tert-butyl ester, has the following structural formula:

[0156]

[0157] Based on the same principles and steps as in Example 4 above, compound B was selected as (2-aminocyclopentyl)carbamic acid tert-butyl ester (CAS: 1193388-07-6) to synthesize R 1 =H, R 2 =H, R 3 and R 4 The TP prodrug compound that cyclizes to form a cyclopentyl group, (2-aminocyclopentyl)carbamic acid tert-butyl ester, has the following structural formula:

[0158]

[0159] Example 5 Study on the water solubility of compound TP-DEA1-4

[0160] A series of target compounds with different concentrations were prepared and dissolved in methanol, and analyzed by high performance liquid chromatography (HPLC). The peak area and compound concentration were plotted to obtain a regression equation to obtain a standard curve of the compound. Another appropriate amount of the target compound was placed in a centrifuge tube, and ultrapure water was added to prepare a saturated solution of the target compound. The supernatant was centrifuged and measured by HPLC injection. The solubility of each TP derivative in water was calculated according to the standard curve. The HPLC analysis method includes: an analytical C18 column (4.6×250mm, 5μm), a mobile phase A: 0.1% trifluoroacetic acid-water (0.1% TFA-H 2 O), mobile phase B: 0.1% trifluoroacetic acid-methanol (0.1% TFA-MeOH), ratio of 40:60, isocratic elution, flow rate 1.0 mL / min; injection volume 20 μL; detection wavelength 220 nm; column temperature 40°C.

[0161] The experimental results show that the solubility of compounds TP-DEA1, TP-DEA2, TP-DEA3 and TP-DEA4 in water are 5.26 mg / mL, 4.23 mg / mL, 2.91 mg / mL and 3.21 mg / mL, respectively, which is more than 170 times higher than the solubility of TP in water of 17 μg / mL.

[0162] Example 6 Metabolic Stability Study of Compound TP-DEA1-4

[0163] Stability study of TP-DEA1, TP-DEA2, TP-DEA3 and TP-DEA4 in mouse plasma: The above compounds (final concentration of 10 μM) were incubated with mouse plasma at 37°C for 0 h, 1 h, 4 h, 8 h, 12 h, 24 h and 36 h, respectively, and then twice the volume of acetonitrile was added to terminate the reaction. The samples were vortexed and mixed at 4°C, centrifuged at 12000 g for 10 min, and the supernatant was taken for HPLC analysis.

[0164] Stability study of TP-DEA1, TP-DEA2, TP-DEA3 and TP-DEA4 in PBS: The above compounds (final concentration was 10 μM) were incubated with PBS (pH = 7.4) at 37°C for 0 h, 1 h, 4 h, 8 h, 12 h, 24 h and 36 h, respectively, and then twice the volume of acetonitrile was added to terminate the reaction. The samples were vortexed and mixed at 4°C, centrifuged at 12000 g for 10 min, and the supernatant was taken for HPLC analysis.

[0165] HPLC chromatographic conditions: mobile phase A: 0.1% trifluoroacetic acid-water, mobile phase B: 0.1% trifluoroacetic acid-methanol, binary gradient elution, flow rate 1.0 mL / min; 0-3 min, 10% to 40% mobile phase B; 3-18 min, 40% mobile phase B; 18-20 min, 40% to 90% mobile phase B, 20-25 min, 90% mobile phase B, 25-30 min, 90% to 10% mobile phase B; detection wavelength is 220 nm; column temperature is 40 °C.

[0166] The experimental results showed that the half-lives of compounds TP-DEA1, TP-DEA2, TP-DEA3, and TP-DEA4 in mouse plasma were 17.3h, 13.3h, 1.79h, and 4.62h, respectively; and the half-lives in PBS were 25.2h, 17.7h, 2.46h, and 5.82h, respectively. This indicates that the conversion of the above compounds is not dependent on the metabolic conversion of hydrolases in plasma. Figure 1 The conversion of TP-DEA2 in mouse plasma (Panel A) and PBS buffer (Panel B) is shown.

[0167] Example 7 Pharmacokinetic study of compound TP-DEA2 in mice

[0168] 32 healthy male Kunming mice with an average body weight of 20-25g were selected and randomly divided into 4 groups, 8 mice in each group, 4 males and 4 females. After TP-DEA2 was injected into the tail vein at a dose of 1 mg / kg, blood was collected from the mouse eye sockets at 0.085, 0.5, 1, 4, 8, 12, 24, and 48h, and plasma samples were collected by centrifugation at 1200g for 10min. 100μL of hydrocortisone (internal standard) was added to a centrifuge tube, concentrated, 100μL of plasma sample was added, and then 300μL of methanol (MeOH) was added, vortexed, centrifuged to obtain the supernatant, dried with nitrogen, and reconstituted (50μL MeOH + 50μL H 2 O), vortexed and centrifuged, and the samples were analyzed by LC-MS (MeOH + 0.1% TEA: H 2 O=35%:65%) detection analysis. The pharmacokinetic parameters of compound TP-DEA2 in mice were calculated by DAS 3.0 and non-compartmental model.

[0169] Figure 2The metabolism of TP-DEA2 in mouse plasma is shown. The results show that the half-life of compound TP-DEA2 after intravenous injection is 7.72±1.05h, the peak blood concentration is 212.07±10.85μg / L, the area under the drug-time curve is 1098.26±26.04μg / L·h, and the average residence time is 14.84±2.59h. It can be seen from the drug-time curve that compound TP-DEA2 is eliminated slowly in mice. When it circulates in the body for 24h, the concentration of the metabolite TP reaches a peak. During the period from 0h to 24h, compound TP-DEA2 is slowly eliminated. After 24h, TP may be excreted from the body through urine or feces.

[0170] Example 8 Study on the anti-idiopathic pulmonary fibrosis effect of compound TP-DEA2 in vivo

[0171] 6-8 week old C57BL / 6 mice (20-25g) were selected and bleomycin (3mg / kg) was directly injected through the trachea to obtain a mouse pulmonary fibrosis (IPF) model. The mice were divided into five groups: blank control group, model group, nibendazim (BIBF1120) group (60mg / kg, po), low-dose compound TP-DEA2 group (0.33mg / kg, L) and high-dose compound TP-DEA2 group (0.66mg / kg, H). The drug was administered on the first day of bleomycin induction or the fifth day after bleomycin induction. The positive control group was orally administered with BIBF1120 (dissolved in 0.5% sodium carboxymethylcellulose (MC) + 0.2% Tween80 + 99.3% H) once a day. 2 O), and the compound TP-DEA2 group were intraperitoneally injected with the corresponding concentration of compound TP-DEA2 (dissolved in H 2 O). After 14 days of continuous administration, the following operations were performed: (1) Blood was collected and serum was separated. The serum ALT, AST, BUN and creatine concentrations were detected using ALT (Wuhan Huamei Biotechnology Co., Ltd.; CAS: CSB-E16539m), AST (Wuhan Huamei Biotechnology Co., Ltd.; CAS: CSB-E12649m), BUN (Qingdao Jieshikang Biotechnology Co., Ltd.; CAS: SJH-033595) and Creatine (Shanghai Huabang Biotechnology Co., Ltd.; CAS: HB-P9S3251X) kits. (2) The animals were weighed and killed. After taking pictures of the tissues, the liver, kidney and lung tissues were immersed in 10% formalin for pathological staining observation.

[0172] Figure 3The serological indicators of mice after continuous intraperitoneal injection of compound TP-DEA2 for two weeks are shown, wherein Figure A is the quantitative detection of liver function indicators (ALT and AST) after administration of the mice, and Figure B is the quantitative detection of renal function indicators (BUN and Creatine), and sham represents the non-administered group. Figure 4 The H&E staining of kidney (upper) and liver (lower) tissue sections after continuous intraperitoneal injection of compound TP-DEA2 for two weeks is shown. Sham represents the group without drug administration. The experimental results show that after continuous intraperitoneal injection of compound TP-DEA2 into mice for two weeks, there is no significant difference between the TP-DEA2 administration group and the normal control group in terms of serological indicators or tissue section observation, indicating that TP-DEA2 has no significant toxic side effects on the liver and kidneys.

[0173] Figure 5 The staining diagram of the section of the mouse lung tissue after continuous intraperitoneal injection of compound TP-DEA2 into the mouse for two weeks is shown. In the mouse IPF model induced by bleomycin, compound TP-DEA2 can significantly reduce bleomycin-induced lung tissue inflammation and inhibit bleomycin-induced lung tissue fibrosis after continuous administration for 2 weeks. It can be seen that compound TP-DEA2 can significantly improve bleomycin-induced mouse lung tissue damage, and the high-dose group of compound TP-DEA2 improves the pathological fibrosis of mouse lung tissue better than the positive drug nibnida. The water-soluble triptolide prodrug compound of the present invention has a good in-depth research value in anti-IPF.

[0174] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of a water-soluble triptolide prodrug compound in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that The water-soluble triptolide prodrug compound is a compound as shown in Formula I or a pharmaceutically acceptable salt thereof: In the formula, R 1 , R 2 , R 3 and R 4 independently selected from hydrogen, methyl or ethyl; Or, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 The C atoms bonded to it combine with each other to form phenyl, cyclohexyl or cyclopentyl groups; Or, R 1 and R 3 are independently selected from hydrogen, methyl or ethyl, R 2 and R 4 The N atom and the C atom bonded thereto are combined with each other to form a pyrrolidyl group.

2. Use of the water-soluble triptolide prodrug compound according to claim 1 in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 Selected from hydrogen; Or, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 The C atoms to which it is bonded combine with each other to form a phenyl group; Or, R 1 is selected from hydrogen, methyl or ethyl, R 3 Selected from hydrogen, R 2 and R 4 The N atom and the C atom bonded thereto are combined with each other to form a pyrrolidyl group.

3. Use of the water-soluble triptolide prodrug compound according to claim 1 in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that The water-soluble triptolide prodrug compound is selected from any one of TP-DEA1 to TP-DEA4 or a pharmaceutically acceptable salt thereof; 4. Use of the water-soluble triptolide prodrug compound according to claim 1 in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that The preparation method of the water-soluble triptolide prodrug compound comprises the following steps: S1, dissolving triptolide and p-nitrophenyl chloroformate in an organic solvent A, adding a base and a catalyst A under the protection of an inert gas, and performing an esterification reaction to obtain a compound of formula A; The structural formula of the compound of formula A is: S2, dissolving the compound of formula A and the compound of formula B in an organic solvent B, adding a catalyst B, and performing an acylation reaction to obtain a compound of formula C; The structural formula of the compound of formula B is: The structural formula of the compound of formula C is: S3, dissolving the compound of formula C in an organic solvent C, adding an organic acid, and performing a deamination protecting agent reaction to obtain a compound of formula I; In the above formula, R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, methyl or ethyl, R 5 is selected from benzyloxycarbonyl, tert-butyloxycarbonyl, benzyl or p-methoxybenzyl; or, R 1 and R 2 are independently selected from hydrogen, methyl or ethyl, R 3 and R 4 The C atoms bonded to it combine with each other to form phenyl, cyclohexyl or cyclopentyl groups, R 5 is selected from benzyloxycarbonyl, tert-butyloxycarbonyl, benzyl or p-methoxybenzyl; or, R 1 and R 3 are independently selected from hydrogen, methyl or ethyl, R 2 and R 4 The N atom and C atom bonded to it combine with each other to form a pyrrolidinyl group, R 5 is selected from benzyloxycarbonyl, tert-butyloxycarbonyl, benzyl or p-methoxybenzyl.

5. Use of the water-soluble triptolide prodrug compound according to claim 4 in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that In step S1, the molar ratio of the triptolide, the p-nitrophenyl chloroformate, the base and the catalyst A is 1:5:5:5, the base is triethylamine, and the catalyst A is 4-dimethylaminopyridine.

6. Use of the water-soluble triptolide prodrug compound according to claim 4 in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that In step S2, the molar ratio of the compound of formula A, the compound of formula B and the catalyst B is 1:1-1.6:0.6-1.6, and the catalyst B is triethylamine or N,N-diisopropylethylamine.

7. Use of the water-soluble triptolide prodrug compound according to claim 4 in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that In step S2, the compound of formula B is selected from at least one of the following formulae; 8. Use of the water-soluble triptolide prodrug compound according to claim 4 in the preparation of a drug for treating idiopathic pulmonary fibrosis, It is characterized in that In step S3, the organic acid is trifluoroacetic acid or an acetic acid solution containing hydrogen bromide.